[O-41] Oral Session 41 Muscle diseases

[O-41-5] Evaluation of drug candidates for myotonic dystrophy type 1 using patient iPSCs

^○Mika Suga^1,2, Takayuki Kondo^1,2,3, Keiko Imamura^1,2,3, Yasue Okanishi¹, Ran Shibukawa^1,2, Yukako Sagara¹, Kayoko Tsukita^1,2, Takako Enami^2,3, Takashi Kimura⁴, Haruhisa Inoue^1,2,3 (1.iPSC-baced Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Japan, 2.Dept. of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, 3.Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), 4.Division of Neurology, Dept. of Internal Medicine, Hyogo College of Medicine)